Open-Label Memantine in Fragile X Syndrome (original) (raw)

References

• Aman, M. G., Singh, N. N., Stewart, A. W., & Field, C. J. (1985). The aberrant behavior checklist: A behavior rating scale for the assessment of treatment effects. American Journal of Mental Deficiency, 5, 485–491.
  Google Scholar
• American Psychiatric Association. (2000). Diagnostic and statistical manual of mental disorders (text revision) (4th ed.). Washington, D.C.: American Psychiatric Association.
  Book Google Scholar
• Bailey, D. B., Jr., Hatton, D. D., Skinner, M., & Mesibov, G. (2001). Autistic behavior, FMR1 protein, and developmental trajectories in young males with fragile X syndrome. Journal of Autism and Developmental Disorders, 31(2), 165–174.
  Article PubMed Google Scholar
• Bassell, G. J., & Gross, C. (2008). Reducing glutamate signaling pays off in fragile X. Nature Medicine, 14(3), 249–250.
  Article PubMed Google Scholar
• Bear, M. F. (2005). Therapeutic implications of the mGluR theory of fragile X mental retardation. Genes, Brain, and Behavior, 4(6), 393–398.
  Article PubMed Google Scholar
• Bear, M. F., Dolen, G., Osterweil, E., & Nagarajan, N. (2008). Fragile X: Translation in action. Neuropsychopharmacology, 33(1), 84–87.
  Article PubMed Google Scholar
• Bear, M. F., Huber, K. M., & Warren, S. T. (2004). The mGluR theory of fragile X mental retardation. Trends in Neurosciences, 27(7), 370–377.
  Article PubMed Google Scholar
• Berry-Kravis, E., Hessl, D., Coffey, S., Hervey, C., Schneider, A., Yuhas, J., et al. (2009). A pilot open label, single dose trial of fenobam in adults with fragile X syndrome. Journal of Medical Genetics, 46(4), 266–271.
  Article PubMed Google Scholar
• Berry-Kravis, E., Krause, S. E., Block, S. S., Guter, S., Wuu, J., Leurgans, S., et al. (2006). Effect of CX516, an AMPA-modulating compound, on cognition and behavior in fragile X syndrome: A controlled trial. Journal of Child and Adolescent Psychopharmacology, 16(5), 525–540.
  Article PubMed Google Scholar
• Berry-Kravis, E., & Potanos, K. (2004). Psychopharmacology in fragile X syndrome—present and future. Mental Retardation and Developmental Disabilities Research Reviews, 10(1), 42–48.
  Article PubMed Google Scholar
• Chez, M. G., Aimonovitch, M., Buchanan, T., Mrazek, S., & Tremb, R. J. (2004). Treating autistic spectrum disorders in children: Utility of the cholinesterase inhibitor rivastigmine tartrate. Journal of Child Neurology, 19(3), 165–169.
  PubMed Google Scholar
• Chez, M. G., Burton, Q., Dowling, T., Chang, M., Khanna, P., & Kramer, C. (2007). Memantine as adjunctive therapy in children diagnosed with autistic spectrum disorders: An observation of initial clinical response and maintenance tolerability. Journal of Child Neurology, 22(5), 574–579.
  Article PubMed Google Scholar
• Clifford, S., Dissanayake, C., Bui, Q. M., Huggins, R., Taylor, A. K., & Loesch, D. Z. (2007). Autism spectrum phenotype in males and females with fragile X full mutation and premutation. Journal of Autism and Developmental Disorders, 37(4), 738–747.
  Article PubMed Google Scholar
• Constantino, J. N., Davis, S. A., Todd, R. D., Schindler, M. K., Gross, M. M., Brophy, S. L., et al. (2003). Validation of a brief quantitative measure of autistic traits: Comparison of the social responsiveness scale with the autism diagnostic interview-revised. Journal of Autism and Developmental Disorders, 33(4), 427–433.
  Article PubMed Google Scholar
• Dolen, G., & Bear, M. F. (2005). Courting a cure for fragile X. Neuron, 45(5), 642–644.
  Article PubMed Google Scholar
• Dolen, G., & Bear, M. F. (2008). Role for metabotropic glutamate receptor 5 (mGluR5) in the pathogenesis of fragile X syndrome. Journal of Physiology, 586(6), 1503–1508.
  Article PubMed Google Scholar
• DuPaul, G., Power, T., Anastopaulus, A., & Reid, R. (1998). ADHD rating scale IV: Checklists, norms, and clinical interpretation. New York: Guilford.
  Google Scholar
• Erickson, C. A., & Chambers, J. E. (2006). Memantine for disruptive behavior in autistic disorder. Journal of Clinical Psychiatry, 67(6), 1000.
  Article PubMed Google Scholar
• Erickson, C. A., Posey, D. J., Stigler, K. A., Mullett, J., Katschke, A. R., & McDougle, C. J. (2007). A retrospective study of memantine in children and adolescents with pervasive developmental disorders. Psychopharmacology (Berl), 191(1), 141–147.
  Article Google Scholar
• Evans, S. M., Levin, F. R., Brooks, D. J., & Garawi, F. (2007). A pilot double-blind treatment trial of memantine for alcohol dependence. Alcoholism, Clinical and Experimental Research, 31(5), 775–782.
  Article PubMed Google Scholar
• Findling, R. L., McNamara, N. K., Stansbrey, R. J., Maxhimer, R., Periclou, A., Mann, A., et al. (2007). A pilot evaluation of the safety, tolerability, pharmacokinetics, and effectiveness of memantine in pediatric patients with attention-deficit/hyperactivity disorder combined type. Journal of Child and Adolescent Psychopharmacology, 17(1), 19–33.
  Article PubMed Google Scholar
• Florencia, G., Irene, S., & Veronica, F. (2006). Fragile-X mental retardation: Molecular diagnosis in Argentine patients. Journal of Biochemistry and Molecular Biology, 39(6), 766–773.
  PubMed Google Scholar
• Gerard, B., Le Heuzey, M. F., Brunie, G., Lewine, P., Saiag, M. C., Cacheux, V., et al. (1997). Systematic screening for fragile X syndrome in a cohort of 574 mentally retarded children. Annales de Genetique, 40(3), 139–144.
  PubMed Google Scholar
• Guy, W. (1976). ECDEU assessment manual for psychopharmacology, Publication No. 76–338. Rockville, MD: U.S. DHEW, NIMH.
  Google Scholar
• Huber, K. M., Gallagher, S. M., Warren, S. T., & Bear, M. F. (2002). Altered synaptic plasticity in a mouse model of fragile X mental retardation. Proceedings of the National Academy of Sciences of the United States of America, 99(11), 7746–7750.
  Article PubMed Google Scholar
• Lieberman, J. A., Papadakis, K., Csernansky, J., Litman, R., Volavka, J., Jia, X. D., et al. (2008). A randomized, placebo-controlled study of memantine as adjunctive treatment in patients with schizophrenia. Neuropsychopharmacology, 34(5), 1322–1329.
  Article PubMed Google Scholar
• Lord, C., Rutter, M., Goode, S., Heemsbergen, J., Jordan, H., Mawhood, L., et al. (1989). Autism diagnostic observation schedule: A standardized observation of communicative and social behavior. Journal of Autism and Developmental Disorders, 19(2), 185–212.
  Article PubMed Google Scholar
• Lord, C., Rutter, M., & Le Couteur, A. (1994). Autism diagnostic interview-revised: A revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. Journal of Autism and Developmental Disorders, 24(5), 659–685.
  Article PubMed Google Scholar
• Mobius, H. J., Stoffler, A., & Graham, S. M. (2004). Memantine hydrochloride: Pharmacological and clinical profile. Drugs Today (Barcelona), 40(8), 685–695.
  Article Google Scholar
• Muhonen, L. H., Lonnqvist, J., Juva, K., & Alho, H. (2008). Double-blind, randomized comparison of memantine and escitalopram for the treatment of major depressive disorder comorbid with alcohol dependence. Journal of Clinical Psychiatry, 69(3), 392–399.
  Article PubMed Google Scholar
• Owley, T., Salt, J., Guter, S., Grieve, A., Walton, L., Ayuyao, N., et al. (2006). A prospective, open-label trial of memantine in the treatment of cognitive, behavioral, and memory dysfunction in pervasive developmental disorders. Journal of Child and Adolescent Psychopharmacology, 16(5), 517–524.
  Article PubMed Google Scholar
• Parsons, C. G., & Gilling, K. (2007). Memantine as an example of a fast, voltage-dependent, open channel N-methyl-d-aspartate receptor blocker. Methods in Molecular Biology, 403, 15–36.
  Article PubMed Google Scholar
• Pilpel, Y., Kolleker, A., Berberich, S., Ginger, M., Frick, A., Mientjes, E., et al. (2008). Synaptic ionotropic glutamate receptors and plasticity are developmentally altered in the CA1 field of FMR1 KO mice. The Journal of Physiology, 587(Pt 4), 787–804.
  Article PubMed Google Scholar
• Reisberg, B., Doody, R., Stoffler, A., Schmitt, F., Ferris, S., & Mobius, H. J. (2003). Memantine in moderate-to-severe Alzheimer’s disease. New England Journal of Medicine, 348(14), 1333–1341.
  Article PubMed Google Scholar
• Rogers, S. J., Wehner, D. E., & Hagerman, R. (2001). The behavioral phenotype in fragile X: Symptoms of autism in very young children with fragile X syndrome, idiopathic autism, and other developmental disorders. Journal of Developmental and Behavioral Pediatrics, 22(6), 409–417.
  PubMed Google Scholar
• SPSS Inc. (2005). SPSS 13.0 for windows. Chicago, IL: SPSS, Inc.
  Google Scholar
• Tervonen, T. A., Louhivuori, V., Sun, X., Hokkanen, M. E., Kratochwil, C. F., Zebryk, P., et al. (2008). Aberrant differentiation of glutamatergic cells in neocortex of mouse model for fragile X syndrome. Neurobiology of Disease, 33(2), 250–259.
  Article PubMed Google Scholar
• Zarate, C. A., Jr., Singh, J. B., Quiroz, J. A., De Jesus, G., Denicoff, K. K., Luckenbaugh, D. A., et al. (2006). A double-blind, placebo-controlled study of memantine in the treatment of major depression. American Journal of Psychiatry, 163(1), 153–155.
  Article PubMed Google Scholar

Download references